1ZLB Stock Overview
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zai Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.91 |
| 52 Week High | US$2.74 |
| 52 Week Low | US$1.22 |
| Beta | 1.06 |
| 11 Month Change | 18.63% |
| 3 Month Change | 24.84% |
| 1 Year Change | -12.39% |
| 33 Year Change | -78.90% |
| 5 Year Change | n/a |
| Change since IPO | -85.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1ZLB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.1% | 1.0% | 1.5% |
| 1Y | -12.4% | -15.4% | 12.6% |
Return vs Industry: 1ZLB exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 1ZLB underperformed the German Market which returned 12.6% over the past year.
Price Volatility
| 1ZLB volatility | |
|---|---|
| 1ZLB Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1ZLB's share price has been volatile over the past 3 months.
Volatility Over Time: 1ZLB's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,175 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
| 1ZLB fundamental statistics | |
|---|---|
| Market cap | €1.99b |
| Earnings (TTM) | -€267.21m |
| Revenue (TTM) | €289.05m |
6.9x
P/S Ratio-7.4x
P/E RatioIs 1ZLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1ZLB income statement (TTM) | |
|---|---|
| Revenue | US$322.71m |
| Cost of Revenue | US$376.55m |
| Gross Profit | -US$53.84m |
| Other Expenses | US$244.49m |
| Earnings | -US$298.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.04 |
| Gross Margin | -16.68% |
| Net Profit Margin | -92.44% |
| Debt/Equity Ratio | 10.0% |
How did 1ZLB perform over the long term?
See historical performance and comparison